Rekrutierung

Eingeschlossene Patienten: 23.123 (Stand 01. November 2024)
Amgevita® (Adalimumab)	232
Benepali® (Etanercept)	1231
Cimzia® (Certolizumab)	1038
Enbrel® (Etanercept)	2872
Erelzi® (Etanercept)	566
Flixabi® (Infliximab)	10
Hukyndra® (Adalimumab)	8
Hulio® (Adalimumab)	258
Humira® (Adalimumab)	2910
Hyrimoz® (Adalimumab)	239
Idacio® (Adalimumab)	66
Imraldi® (Adalimumab)	230
Inflectra™ (Infliximab)	17
Jyseleca® (Filgotinib)	153
Kevzara® (Sarilumab)	223
Kineret® (Anakinra)	89
MabThera® (Rituximab)	1459
Nepexto® (Etanercept)	90
Olumiant® (Baricitinib)	545
Orencia® (Abatacept)	990
Remicade® (Infliximab)	762
Remsima® (Infliximab)	25
Rinvoq® (Upadacitinib)	311
Rixathon® (Rituximab)	20
RoActemra® (Tocilizumab)	1378
Ruxience® (Rituximab)	1
Simponi® (Golimumab)	473
Truxima® (Rituximab)	2
Tyenne® (Tocilizumab)	31
Xeljanz® (Tofacitinib)	397
Yuflyma® (Adalimumab)	46
Zessly® (Infliximab)	2
Kontrollen	6449